• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤溶酶原激活物抑制剂-1缺乏可预防小鼠颈动脉粥样硬化进展。

Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.

作者信息

Eitzman D T, Westrick R J, Xu Z, Tyson J, Ginsburg D

机构信息

Divisions of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA.

出版信息

Blood. 2000 Dec 15;96(13):4212-5.

PMID:11110693
Abstract

Dissolution of the fibrin blood clot is regulated in large part by plasminogen activator inhibitor-1 (PAI-1). Elevated levels of plasma PAI-1 may be an important risk factor for atherosclerotic vascular disease and are associated with premature myocardial infarction. The role of the endogenous plasminogen activation system in limiting thrombus formation following atherosclerotic plaque disruption is unknown. This study found that genetic deficiency for PAI-1, the primary physiologic regulator of tissue-type plasminogen activator (tPA), prolonged the time to occlusive thrombosis following photochemical injury to carotid atherosclerotic plaque in apolipoprotein E-deficient (apoE(-/-)) mice. However, anatomic analysis revealed a striking difference in the extent of atherosclerosis at the carotid artery bifurcation between apoE(-/-) mice and mice doubly deficient for apoE and PAI-1 (PAI-1(-/-)/apoE(-/-)). Consistent with a previous report, PAI-1(+/+)/apoE(-/-)and PAI-1(-/-)/apoE(-/-) mice developed similar atherosclerosis in the aortic arch. The marked protection from atherosclerosis progression at the carotid bifurcation conferred by PAI-1 deficiency suggests a critical role for PAI-1 in the pathogenesis of atherosclerosis at sites of turbulent flow, potentially through the inhibition of fibrin clearance. Consistent with this hypothesis, intense fibrinogen/fibrin staining was observed in atherosclerotic lesions at the carotid bifurcation compared to the aortic arch. These observations identify significant differences in the pathogenesis of atherosclerosis at varying sites in the vascular tree and suggest a previously unappreciated role for the plasminogen activation system in atherosclerosis progression at sites of turbulent flow. (Blood. 2000;96:4212-4215)

摘要

纤维蛋白血凝块的溶解在很大程度上受纤溶酶原激活物抑制剂-1(PAI-1)调节。血浆PAI-1水平升高可能是动脉粥样硬化性血管疾病的重要危险因素,并与早发性心肌梗死相关。内源性纤溶酶原激活系统在限制动脉粥样硬化斑块破裂后血栓形成中的作用尚不清楚。本研究发现,作为组织型纤溶酶原激活物(tPA)的主要生理调节因子,PAI-1基因缺陷延长了载脂蛋白E缺陷(apoE(-/-))小鼠颈动脉粥样硬化斑块光化学损伤后闭塞性血栓形成的时间。然而,解剖学分析显示,apoE(-/-)小鼠与apoE和PAI-1双缺陷(PAI-1(-/-)/apoE(-/-))小鼠颈动脉分叉处动脉粥样硬化的程度存在显著差异。与先前的报告一致,PAI-1(+/+)/apoE(-/-)和PAI-1(-/-)/apoE(-/-)小鼠在主动脉弓处发展出相似的动脉粥样硬化。PAI-1缺陷对颈动脉分叉处动脉粥样硬化进展的显著保护作用表明,PAI-1在湍流部位动脉粥样硬化的发病机制中起关键作用,可能是通过抑制纤维蛋白清除来实现的。与这一假设一致,与主动脉弓相比,在颈动脉分叉处的动脉粥样硬化病变中观察到强烈的纤维蛋白原/纤维蛋白染色。这些观察结果确定了血管树不同部位动脉粥样硬化发病机制的显著差异,并表明纤溶酶原激活系统在湍流部位动脉粥样硬化进展中具有先前未被认识到的作用。(《血液》。2000年;96:4212 - 4215)

相似文献

1
Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.纤溶酶原激活物抑制剂-1缺乏可预防小鼠颈动脉粥样硬化进展。
Blood. 2000 Dec 15;96(13):4212-5.
2
Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice.1型纤溶酶原激活物抑制剂可增强易患动脉粥样硬化小鼠氧化血管损伤后的内膜增生。
Circulation. 2001 Jun 26;103(25):3105-10. doi: 10.1161/01.cir.103.25.3105.
3
Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.低密度脂蛋白受体缺陷和载脂蛋白E缺陷小鼠的动脉粥样硬化进展与纤溶酶原激活物抑制剂-1的基因改变无关。
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):846-52. doi: 10.1161/01.atv.20.3.846.
4
Lack of urokinase plasminogen activator promotes progression and instability of atherosclerotic lesions in apolipoprotein E-knockout mice.尿激酶型纤溶酶原激活剂的缺乏促进载脂蛋白E基因敲除小鼠动脉粥样硬化病变的进展和不稳定性。
Thromb Haemost. 2007 Jul;98(1):220-7.
5
Factor XII regulates the pathological process of thrombus formation on ruptured plaques.因子 XII 调节破裂斑块上血栓形成的病理过程。
Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1674-80. doi: 10.1161/ATVBAHA.114.303315. Epub 2014 May 22.
6
Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries.1型纤溶酶原激活物抑制剂可增加球囊损伤大鼠颈动脉的新生内膜形成。
Circulation. 2001 Oct 16;104(16):1972-1. doi: 10.1161/hc4101.097110.
7
Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1.动脉粥样硬化易患小鼠中血栓形成增强与纤溶酶原激活物抑制剂-1的动脉表达增加有关。
Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2097-103. doi: 10.1161/01.ATV.0000097766.36623.DF. Epub 2003 Sep 25.
8
Atheroprotective role of C5ar2 deficiency in apolipoprotein E-deficient mice.C5ar2缺乏在载脂蛋白E缺乏小鼠中的抗动脉粥样硬化作用。
Thromb Haemost. 2015 Oct;114(4):848-58. doi: 10.1160/TH14-12-1075. Epub 2015 Jun 18.
9
Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.纤溶酶原激活物抑制剂-1和玻连蛋白促进小鼠血管血栓形成。
Blood. 2000 Jan 15;95(2):577-80.
10
Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.纤溶酶原激活物抑制剂-1是动脉溶栓抵抗的主要决定因素。
Circulation. 1999 Jun 15;99(23):3050-5. doi: 10.1161/01.cir.99.23.3050.

引用本文的文献

1
Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review).肥胖与慢性炎症在代谢功能紊乱表现中的分子和病理生理学关系及其炎症介导的治疗选择(综述)。
Mol Med Rep. 2024 Jun;29(6). doi: 10.3892/mmr.2024.13219. Epub 2024 Apr 12.
2
Adipokines and Bacterial Metabolites: A Pivotal Molecular Bridge Linking Obesity and Gut Microbiota Dysbiosis to Target.脂联素和细菌代谢产物:连接肥胖和肠道微生物失调与靶点的关键分子桥梁
Biomolecules. 2023 Nov 23;13(12):1692. doi: 10.3390/biom13121692.
3
Obesity, Weight Gain, and Fluid Overload in Peritoneal Dialysis.
腹膜透析中的肥胖、体重增加和液体超负荷
Front Nephrol. 2022 Jun 28;2:880097. doi: 10.3389/fneph.2022.880097. eCollection 2022.
4
Identification of genomic loci regulating platelet plasminogen activator inhibitor-1 in mice.鉴定调控小鼠血小板纤溶酶原激活物抑制剂-1的基因组位点。
J Thromb Haemost. 2023 Oct;21(10):2917-2928. doi: 10.1016/j.jtha.2023.06.018. Epub 2023 Jun 25.
5
Endothelin-1 Stimulates PAI-1 Protein Expression via Dual Transactivation Pathway Dependent ROCK and Phosphorylation of Smad2L.内皮素-1通过依赖ROCK和Smad2L磷酸化的双转录激活途径刺激PAI-1蛋白表达。
Cell J. 2022 Aug 28;24(8):465-472. doi: 10.22074/cellj.2022.7720.
6
PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea?PAI-1:阻塞性睡眠呼吸暂停中血管功能障碍的主要参与者?
Int J Mol Sci. 2022 May 15;23(10):5516. doi: 10.3390/ijms23105516.
7
Adipokines, adiposity, and atherosclerosis.脂联素、肥胖与动脉粥样硬化。
Cell Mol Life Sci. 2022 May 3;79(5):272. doi: 10.1007/s00018-022-04286-2.
8
The Roles and Associated Mechanisms of Adipokines in Development of Metabolic Syndrome.脂肪细胞因子在代谢综合征发生发展中的作用及相关机制。
Molecules. 2022 Jan 6;27(2):334. doi: 10.3390/molecules27020334.
9
A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.一种在多种蛋白酶抑制物中起作用的丝氨酸蛋白酶抑制剂:纤溶酶原激活物抑制剂-1在血栓炎症和心血管疾病中的核心作用
Front Cardiovasc Med. 2021 Apr 16;8:653655. doi: 10.3389/fcvm.2021.653655. eCollection 2021.
10
Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective.心脏病与代谢性脂肪变性之间的相互作用:当代视角
J Clin Med. 2021 Apr 8;10(8):1569. doi: 10.3390/jcm10081569.